RUVBL2 Mouse anti-Canine, Human, Mouse, Rat, Clone: OTI1D9, liquid, TrueMAB
Mouse Monoclonal Antibody
Manufacturer: OriGene TA504285
DescriptionPossesses single-stranded DNA-stimulated ATPase and ATP-dependent DNA helicase (5 ft. to 3 ft.) activity. Component of the NuA4 histone acetyltransferase complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A. This modification may both alter nucleosome - DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription. This complex may be required for the activation of transcriptional programs associated with oncogene and proto-oncogene mediated growth induction, tumor suppressor mediated growth arrest and replicative senescence, apoptosis, and DNA repair. The NuA4 complex ATPase and helicase activities seem to be, at least in part, contributed by the association of RUVBL1 and RUVBL2 with EP400. NuA4 may also play a direct role in DNA repair when recruited to sites of DNA damage. RUVBL2 plays an essential role in oncogenic transformation by MYC and also modulates transcriptional activation by the LEF1/TCF1-CTNNB1 complex. May also inhibit the transcriptional activity of ATF2.
|PBS with 1% BSA, 50% glycerol and 0.02% sodium azide|
|CGI-46, ECP-51, ECP51, INO80J, REPTIN, RVB2, TAP54-beta, TIH2, TIP48, TIP49B|
|-20° C, Avoid Freeze/Thaw Cycles|
|10856, 20174, 292907, 476418|
|Immunohistochemistry (Paraffin), Western Blot|
|Human recombit protein fragment corresponding to amino acids 113-370 of human RUVBL2 produced in HEK293T cell.|
|Canine, Human, Mouse, Rat|
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok